Biology subjects

Gan, B.

Publications and source records attributed to Gan, B..

10 recordsLinked to original sources

bioRxiv2026

Concurrent Stereotactic Body Radiation Therapy and KRAS Inhibition Synergistically Improve Pre-clinical Pancreatic Cancer Treatment

Pancreatic ductal adenocarcinoma (PDAC) is one of the most challenging cancers to treat due to the dismal survival rate, poor post-treatment outcome and profound resistance to a wide range of therapies. With mutant KRAS being a key driver, small molecule inhibitors targeting KRAS or pan-RAS (KRASi) have demonstrated exciting preclinical and early clinical anti-tumor efficacy, and the pan-RAS(ON) inhibitor daraxonrasib (RMC-6236) recently achieved Phase 3 clinically meaningful improvements in patient survival compared to chemotherapy. But resistance to RAS/KRAS inhibitor inevitably develops, which limits and compromises the treatment outcome. In this study, we investigated the combination of stereotactic body radiation therapy (SBRT) and KRAS inhibition (MRTX1133 and daraxonrasib) in the treatment of preclinical PDAC models. We found that this combination strategy synergistically suppresses PDAC cell growth in vitro and enhances tumor control while minimizing local recurrence in orthotopically implanted KPC (LSL-KrasG12D/+;Trp53R172H/+;Pdx1-Cre) murine PDAC tumors in vivo. As radiation therapy (RT) induces ferroptosis in multiple cancer types and mutant KRAS promotes various anti-ferroptotic mechanisms, we tested the role of ferroptosis in promoting tumor-control efficacy. Intriguingly, the addition of a ferroptosis inhibitor, liproxstatin-1, to the combination therapy significantly abrogated the in vivo synergism between SBRT and KRAS inhibition, suggesting that treatment-induced ferroptosis at least partially drives the synergistic efficacy of this combination strategy. Our study indicates that this SBRT-KRASi combination has the potential to overcome treatment resistance and improve outcomes in PDAC patients. These data directly support the design of a planned multi-center Phase 2 clinical trial with this combination strategy in locally advanced PDAC.

cancer biology↗

bioRxiv2026

Effects of Left Atrial Wall Thickness on Myocardial Mechanics and Blood Dynamics using Multiscale Modeling

PurposePatient-specific models of left atrial (LA) mechanics often assume uniform left atrial wall thickness (LAWT), but the effect of LAWT on the mechanics and hemodynamics remains less quantified. MethodsFour LA myocardium models were built from gated CTA images: a baseline variable thickness (VT#0), two reduced-dilation variants, and a 2mm uniform thickness model. Multi-scale mechanics and blood flow simulations were performed across all the thickness variants using model parameters personalized on the baseline model. Predicted displacements, wall stresses and strains, and hemodynamics were compared. ResultsAcross all LAWT variants, myocardial volume spanned 14.4-19.9mL (38%), while cavity volume remained mostly within 5% of image data throughout the cardiac cycle. Circulatory system output, myocardial displacements, and strains varied by 5-6% relative to the baseline model. Instantaneous stresses increased by up to 19% in the thinner variable thickness models and decreased by up to 16% in the uniformly thick case. Globally, the area under low time-averaged wall shear stress (TAWSS) varied between 23% and 30% across all thickness variants, while LA exposed to elevated oscillatory shear index (OSI) increased from nearly 6% to 19%. Over 90% of LAA was exposed to low shear, but the high-OSI area increased from 7% in VT#0 to over 30% in Uniform. ConclusionA personalized multiscale modeling framework was leveraged to demonstrate that the left atrial myocardial stresses and oscillatory shear had a greater sensitivity to local wall thickness representation compared to cavity volumes, tissue displacements, strains, and mean blood shear.

bioengineering↗

bioRxiv2026

Improve the Efficacy of B7-H3-Targeting Antibody-Drug Conjugate DS-7300a in TP53-deficient Tumors by Inducing Ferroptosis

Immune checkpoint B7-H3 is an emerging target for immunotherapy. DS-7300a is an advanced B7-H3-targeting antibody-drug conjugate (ADC) warheaded with the topoisomerase I inhibitor DXd. DS-7300a has demonstrated clinical activity, but molecular biomarkers to predict its therapeutic response remain elusive. TP53 is one of the most mutated tumor suppressor genes across cancers, and effective therapies are urgently needed for TP53-deficient cancers. Using prostate cancer (PCa) as a model system, we reported that DS-7300as anti-tumor efficacy is highly dependent on functional p53 in cancer cells, and TP53 defects confer resistance to DS-7300a. Mechanistically, we found that DS-7300a and its payload, DXd, induce DNA damage and activate the ATM/ATR/CHK signaling cascade, thereby stabilizing p53 and inducing a pro-apoptotic and senescence-associated transcriptome. In contrast, TP53-deficient cells fail to detect DXd-induced DNA damage, maintain a high proliferation rate, and exhibit low levels of apoptosis and senescence, thereby conferring resistance to DS-7300a. Ferroptosis is an iron-dependent form of regulated cell death triggered by lipid peroxidation, which is mechanistically and morphologically distinct from apoptosis. Interestingly, DS-7300a treatment elevates lipid peroxidation in TP53-deficient cancer cells and upregulates glutathione peroxidase 4 (GPX4), an antioxidant enzyme that mitigates lipid peroxidation. Using isogeneic xenograft models and a newly developed humanized B7-H3 PCa model, we demonstrated that inducing ferroptosis by pharmacological inhibition of GPX4 enhances DS-7300as efficacy in TP53-deficient tumors. Our studies demonstrate that TP53 status dictates anti-tumor responses to DS-7300a, and ferroptosis induction represents a promising therapeutic approach to overcome resistance to DS-7300a in malignancies harboring TP53 defects.

cancer biology↗

bioRxiv2026

Cigarette smoke induces colon cancer by regulating the gut microbiota and related metabolites

The causal relationship between smoking and colorectal cancer (CRC) remains unclear. In this study, a cigarette smoke-exposed mouse model demonstrated that smoking significantly increased CRC incidence by inducing gut microbiota dysbiosis and altering related metabolites. Smoke exposure reduced beneficial bacteria (e.g., Lactobacillus), increased harmful bacteria (e.g., Firmicutes and Clostridium), elevated metabolites such as histamine, and suppressed the tumor suppressor genes PARG, CPT2, and ALDH1A1, thereby promoting tumor development. Functional assays in CRC cell lines further confirmed that CPT2 knockdown enhanced malignant phenotypes, including proliferation, migration, and invasion. Clinical analysis showed that these genes were markedly downregulated in smoking-related CRC patients, with strong diagnostic value (AUC > 0.8). ConclusionSmoking promotes CRC by inducing gut microbiota dysbiosis, metabolic reprogramming, and suppression of tumor suppressor genes, particularly CPT2. These findings highlight the importance of smoking cessation in CRC prevention and provide potential biomarkers for early diagnosis and therapeutic intervention.

bioinformatics↗

bioRxiv2025

A Multi-Disciplinary Framework for Decoding S1PR1-Selective Agonism

Sphingosine-1-phosphate (S1P), a key metabolite of sphingolipids, plays crucial roles in a wide range of physiological and pathological processes. S1P primarily exerts its functions by binding to G protein-coupled sphingosine-1-phosphate receptors (S1PRs), which include five subtypes (S1PR1-5), thereby activating these receptors and their downstream signaling pathways. Understanding the molecular determinants that govern agonist selectivity among different S1PR subtypes is vital for the rational and precise development of targeted therapeutic agents. Here, four cryo-electron microscopy structures of agonist-bound S1PR1-Gi complexes are reported. Through an integrated approach combining structural analysis, molecular dynamics simulations, and pharmacological assays, the molecular basis for the selectivity of CYM5442, HY-X-1011, Ponesimod, and SAR247799 toward S1PR1 over S1PR3 and S1PR5 is uncovered. Specifically, the selectivity arises from a combination of non-conserved residues within the ligand-binding pocket and at the Gi-protein interface, distinct curved agonist-binding modes oriented toward transmembrane helices 5-7 that cause steric clashes with S1PR3, and the presence of branched moieties at the lower part of three agonists. These features collectively enhance agonist potency and efficacy for S1PR1 while reducing activity at S1PR3 and S1PR5. These findings establish a structural framework for the rational design of next-generation S1PR1 highly selective agonists with improved therapeutic potential.

biochemistry↗

bioRxiv2023

DePARylation is critical for S phase progression and cell survival

Poly(ADP-ribose)ylation or PARylation by PAR polymerase 1 (PARP1) and dePARylation by poly(ADP-ribose) glycohydrolase (PARG) are equally important for the dynamic regulation of DNA damage response. PARG, the most active dePARylation enzyme, is recruited to sites of DNA damage via pADPr-dependent and PCNA-dependent mechanisms. Targeting dePARylation is considered an alternative strategy to overcome PARP inhibitor resistance. However, precisely how dePARylation functions in normal unperturbed cells remains elusive. To address this challenge, we conducted multiple CRISPR screens and revealed that dePARylation of S phase pADPr by PARG is essential for cell viability. Loss of dePARylation activity initially induced S phase-specific pADPr signaling, which resulted from unligated Okazaki fragments and eventually led to uncontrolled pADPr accumulation and PARP1/2-dependent cytotoxicity. Moreover, we demonstrated that proteins involved in Okazaki fragment ligation and/or base excision repair regulate pADPr signaling and cell death induced by PARG inhibition. In addition, we determined that PARG expression is critical for cellular sensitivity to PARG inhibition. Additionally, we revealed that PARG is essential for cell survival by suppressing pADPr. Collectively, our data not only identify an essential role for PARG in normal proliferating cells but also provide a potential biomarker for the further development of PARG inhibitors in cancer therapy.

cancer biology↗

bioRxiv2022

The structural basis of itch receptor MRGPRX1 activation

Mas-related G-protein-coupled receptors X1-X4 (MRGPRX1-X4) are four primate-specific receptors that are recently reported to be responsible for many biological processes, including itch sensation, pain transmission, and inflammatory reactions. MRGPRX1 is the first identified human MRGPR, and its expression is restricted to primary sensory neurons. Due to its dual roles in itch and pain signaling pathways, MRGPRX1 has been regarded as a promising target for itch remission and pain inhibition. Here, we reported a cryo-electron microscopy (cryo-EM) structure of Gq-coupled MRGPRX1 in complex with a synthetic agonist compound 16 in an active conformation at an overall resolution of 3.0 angstrom via a NanoBiT tethering strategy. Compound 16 is a new pain-relieving compound with high potency and selectivity to MRGPRX1 over opioid receptor. According to the structure analysis, we revealed that MRGPRX1 shares common features of the Gq-mediated receptor activation mechanism of MRGPRX family members. However, the variable residues in orthosteric pocket of MRGPRX1 exhibits the unique agonist recognition pattern, which may facilitate to design MRGPRX1-specific modulators. Together with receptor activation and itch behavior evaluation assays, our study provides a structural snapshot to modify therapeutic molecules for itch relieving and analgesia targeting MRGPRX1.

biochemistry↗

bioRxiv2022

Elimination of Foxo triplets following glucocorticoid incubation dampened metabolic stress and enhanced anti-viral response targets based on transcriptomic analysis

Glucocorticoids, both endogenous and exogenous, are known anti-inflammatory agents with associated adverse effects when administered chronically or in excess. Foxo family members, specifically Foxo1, Foxo3 and Foxo4 have demonstrated to be major regulators of metabolic complications following glucocorticoid action. We employed mouse embryonic fibroblasts as model system and using tamoxifen induced Cre+ recombinase activation, we achieved deletion of the Foxo triplets- Foxo1, Foxo3, and Foxo4. Following incubation of dexamethasone in both wild type and Foxo triplet deleted group, RNA sequencing was performed to reveal the transcriptome. Interestingly, the transcripts involved in initiating metabolic stress like PDK4 and 11 Beta HSD1 were downregulated, whereas transcripts involved in anti-viral response were upregulated following Foxo triplet deletion. The anti-inflammatory property of glucocorticoids was kept intact based on transcripts evaluated including GILZ and COX2. In summary, our study reveals a unique phenomenon where we will be able to manipulate glucocorticoid action by deleting Foxo triplets eliminating the metabolic stress components but enhancing anti-viral response and maintaining their clinical use as an anti-inflammatory agent. This work will lay foundation for a paradigm shift in clinical use of glucocorticoids according to therapeutic advantage with lesser adverse effects

pharmacology and toxicology↗

bioRxiv2022

Structural Insights into Sphingosine-1-phosphate Receptor Activation

As a critical sphingolipid metabolite, sphingosine-1-phosphate (S1P) plays an essential role in immune and vascular systems. There are five S1P receptors, designated as S1PR1-5, encoded in the human genome, and their activities are governed by endogenous S1P, lipid-like S1P mimics, or non-lipid-like therapeutic molecules. Among S1PRs, S1PR1 stands out due to its non-redundant functions, such as the egress of T and B cells from the thymus and secondary lymphoid tissues, making it a potential therapeutic target. However, the structural basis of S1PR1 activation and regulation by various agonists remains unclear. Here we reported four atomic resolution cryo-EM structures of Gi-coupled human S1PR1 complexes: bound to endogenous agonist d18:1 S1P, benchmark lipid-like S1P mimic phosphorylated Fingolimod ((S)-FTY720-P), or non-lipid-like therapeutic molecule CBP-307 in two binding modes. Our results revealed the similarities and differences of activation of S1PR1 through distinct ligands binding to the amphiphilic orthosteric pocket. We also proposed a two-step "shallow to deep" transition process of CBP-307 for S1PR1 activation. Both binding modes of CBP-307 could activate S1PR1, but from shallow to deep transition may trigger the rotation of the N-terminal helix of Gi and further stabilize the complex by increasing the Gi interaction with the cell membrane. We combine with extensive biochemical analysis and molecular dynamic simulations to suggest key steps of S1P binding and receptor activation. The above results decipher the common feature of the S1PR1 agonist recognition and activation mechanism and will firmly promote the development of therapeutics targeting S1P receptors.

biochemistry↗

bioRxiv2018

Crystal structure of the MBD domain of MBD3 in complex with methylated CG DNA

MBD3 is a core subunit of the Mi-2/NuRD complex, and has been previously reported to lack methyl-CpG binding ability. However, recent reports show that MBD3 recognizes both mCG and hmCG DNA with a preference for hmCG, and is required for the normal expression of hmCG marked genes in ES cells. Nevertheless, it is not clear how MBD3 recognizes the methylated DNA. In this study, we carried out structural analysis coupled with isothermal titration calorimetry (ITC) binding assay and mutagenesis studies to address the structural basis for the mCG DNA binding ability of the MBD3 MBD domain. We found that the MBD3 MBD domain prefers binding mCG over hmCG through the conserved arginine fingers, and this MBD domain as well as other mCG binding MBD domains can recognize the mCG duplex without orientation selectivity. Furthermore, we found that the tyrosine-to-phenylalanine substitution at Phe34 of MBD3 is responsible for its weaker mCG DNA binding ability compared to other mCG binding MBD domains. In summary, our study demonstrates that the MBD3 MBD domain is a mCG binder, and also illustrates its binding mechanism to the methylated CG DNA.

biochemistry↗